TL;DR
Developing AI Software as a Medical Device requires more than adding a machine learning model to a healthcare product. AI SaMD is regulated medical software when it is intended to diagnose, treat, mitigate, cure, or prevent disease, or when it meaningfully informs clinical decisions. That means product teams need to define the intended use, understand FDA classification, validate model performance, manage risk, protect patient data, document the software lifecycle, and plan how the model will be monitored after launch.
For AI-powered medical devices, the FDA has moved toward a total product lifecycle approach. The agency maintains a public list of AI-enabled medical devices authorized for marketing in the United States and has issued guidance on Predetermined Change Control Plans, known as PCCPs, for AI-enabled device software functions. A PCCP can allow manufacturers to describe certain future AI software changes in the original marketing submission, so those authorized changes can be implemented later without a new submission for each covered modification.
The safest way to build AI SaMD is to treat compliance, architecture, data governance, cybersecurity, clinical validation, and post-market monitoring as product requirements from day one. Teams that delay regulatory thinking until the end often face rework, unclear claims, weak validation evidence, and launch delays.
Developing AI Software as a Medical Device starts with one question: what clinical role does the software play? If the AI only supports internal operations, the regulatory path may be different from software that detects disease, recommends treatment, triages risk, analyzes medical images, or influences a provider’s clinical decision.
This is where many AI healthcare products run into problems. The team builds the model first, then tries to decide whether it is regulated later. For AI SaMD, that order creates risk. The intended use, user, clinical claim, output type, data source, model behavior, and level of automation all shape the regulatory and technical plan.
As Gaurav Malik, Chief Commercial Officer at CitrusBits, says:
“AI SaMD should not be treated as a model deployment project. It is a medical product lifecycle. The architecture, validation evidence, risk controls, and post-market monitoring plan need to be designed before the first clinical workflow is automated.”
What Is AI Software as a Medical Device?
AI Software as a Medical Device refers to software that uses artificial intelligence or machine learning and performs a medical purpose without being part of a hardware medical device. It may analyze patient data, medical images, waveforms, clinical notes, lab results, vitals, or other healthcare inputs to support diagnosis, monitoring, prediction, triage, or treatment-related decisions.
Examples may include AI software that detects abnormalities in imaging, predicts disease progression, supports clinical decision-making, identifies patient risk, monitors physiological data, or generates outputs that clinicians use in care decisions.
Not all healthcare AI is SaMD. An AI tool used only for scheduling, billing, marketing, or internal operations may not be SaMD. The distinction depends on intended use and claims. If the product is positioned for medical decision support or patient-specific clinical action, regulatory analysis becomes critical.
Applications of AI/ML in Software as a Medical Device
AI/ML SaMD can support a wide range of healthcare use cases.
Common applications include:
- Medical image analysis
- Diagnostic decision support
- Disease risk prediction
- Remote patient monitoring alerts
- Clinical deterioration prediction
- Digital biomarkers
- Triage and prioritization
- Treatment response prediction
- Personalized care recommendations
- Automated measurement or detection workflows
- AI-powered medical device companion software
These applications can create real clinical value, but they also carry risk. A false negative may delay care. A false positive may trigger unnecessary intervention. A biased training dataset may reduce performance for certain patient groups. A model update may change behavior in ways the team did not anticipate.
That is why AI medical device software needs more than model accuracy. It needs risk management, representative data, clinical validation, cybersecurity, change control, and clear documentation.
How to Build AI-Powered SaMD (GIF)
A practical AI SaMD development process should begin before model training.
- Define Intended Use and Claims
Start by defining what the AI product is intended to do, who will use it, what input data it requires, what output it produces, and how that output affects care. Intended use drives classification, validation, labeling, risk analysis, and submission strategy.
- Identify the Clinical Workflow
Map where the AI fits into the workflow. Does it support a physician? Does it alert a nurse? Does it run in the background? Does it generate a diagnostic output? Does the user have enough information to independently review the basis for the recommendation?
This matters because FDA’s Clinical Decision Support guidance clarifies when certain clinical decision support software functions are subject to FDA oversight. The updated guidance focuses on software intended for healthcare professionals and clarifies the scope of FDA oversight for CDS software as devices.
- Build the Data Strategy
AI SaMD needs controlled data pipelines. Teams should define data sources, data quality rules, labeling methods, inclusion and exclusion criteria, training and test splits, bias checks, traceability, and privacy controls.
- Design the Architecture
A compliant AI SaMD architecture should separate core application logic, model services, data ingestion, inference workflows, audit logging, monitoring, user access, and update controls. This makes the system easier to validate, monitor, secure, and maintain.
- Validate Model Performance
Validation should include technical performance and clinical relevance. Teams need evidence that the model performs for the intended population, workflow, and use environment. Performance should be tested against appropriate metrics, thresholds, and clinical acceptance criteria.
- Plan for Human Review
Many AI medical device software products should include human oversight, especially when outputs influence care. The product should make it clear what the AI found, what data informed the output, and what action the user should or should not take.
- Prepare for Post-Market Monitoring
AI models can degrade over time as data, workflows, devices, and populations change. Monitoring should track performance, drift, safety signals, user feedback, cybersecurity events, and real-world usage.
AI SaMD FDA Classification
AI SaMD FDA classification depends on intended use, risk, claims, user, output, and clinical impact. In the U.S., AI-enabled device software may be reviewed through pathways such as 510(k), De Novo, or PMA depending on the product and risk profile. FDA’s PCCP guidance specifically applies to AI-enabled devices reviewed through 510(k), De Novo, and PMA pathways.
Teams should avoid assuming that all AI SaMD follows one pathway. A low-risk monitoring tool, an AI imaging triage tool, and an autonomous diagnostic product may have very different regulatory requirements.
Important classification questions include:
- What disease, condition, or clinical function does the software address?
- Does the AI output diagnose, treat, predict, monitor, or recommend action?
- Is the user a clinician, patient, caregiver, or administrator?
- Can the user independently review the basis for the AI output?
- What harm could occur if the output is wrong?
- Is there a predicate device?
- Will the model be locked or modified over time?
- Are future modifications planned under a PCCP?
Classification should be reviewed early with regulatory experts because it directly affects development evidence, quality processes, validation scope, and launch timeline.
What Regulations Apply to AI SaMD?
The regulatory and compliance landscape depends on the market, product risk, and intended use. For U.S. commercialization, teams should consider FDA medical device requirements, software documentation expectations, quality system requirements, cybersecurity expectations, clinical validation, and post-market obligations.
Important frameworks and considerations include:
- FDA SaMD and medical device regulations
- FDA AI/ML SaMD Action Plan and related AI-enabled device guidance
- Good Machine Learning Practice principles
- Predetermined Change Control Plan guidance for AI-enabled device software functions
- Clinical Decision Support Software guidance where applicable
- Quality management system expectations
- Risk management aligned with medical device practices
- Cybersecurity and secure software development
- HIPAA and data privacy obligations where PHI is involved
The FDA’s AI/ML SaMD Action Plan has been followed by multiple AI-related efforts, including Good Machine Learning Practice guiding principles, PCCP guidance, transparency principles for machine learning-enabled devices, and broader FDA coordination around AI in medical products.
Architecture for AI Medical Device Software
Architecture is where many AI SaMD projects either become scalable or become difficult to validate.
A strong AI medical device software architecture should include:
Data Layer:
Handles data ingestion, formatting, labeling, normalization, storage, privacy controls, and traceability.
Model Layer:
Manages training, versioning, inference, evaluation metrics, and approved model artifacts.
Application Layer:
Presents AI outputs to users with appropriate context, workflow fit, warnings, and usability controls.
Integration Layer:
Connects with EHRs, devices, imaging systems, lab systems, APIs, dashboards, and clinical platforms through controlled interfaces.
Governance Layer:
Tracks access, audit logs, model versions, configuration, change control, user actions, and monitoring data.
Monitoring Layer:
Tracks model drift, performance changes, safety signals, errors, uptime, and feedback after deployment.
For AI SaMD, the architecture must support both product performance and evidence generation. If teams cannot trace which model version generated which output, which input data was used, or how performance changed over time, post-market governance becomes difficult.
PCCP for AI Medical Devices
A Predetermined Change Control Plan is one of the most important FDA concepts for AI-enabled medical device software.
The FDA reviews a PCCP as part of a marketing submission for an AI-enabled device. The purpose is to allow certain planned modifications to be implemented after authorization without requiring a new marketing submission for each covered change, as long as those modifications follow the authorized PCCP.
A PCCP generally helps describe:
- What modifications are planned
- How those modifications will be developed and validated
- How the impact on safety and effectiveness will be assessed
- How risks will be controlled
- What limits define the approved modification plan
This is important because AI models may need updates after launch. Data distributions can change. Clinical workflows may evolve. Performance may need to improve for subgroups. New input devices or settings may be added.
Without a clear change control plan, every meaningful AI update can create regulatory uncertainty. With a well-planned PCCP, teams can define a controlled pathway for certain future updates.
Launch and Post-Market Monitoring
Launching AI SaMD is not the end of development. It is the start of real-world performance management.
Post-market monitoring should include:
- Model performance tracking
- Drift detection
- Error monitoring
- Safety signal review
- User feedback
- Subgroup performance analysis
- Cybersecurity monitoring
- Complaint handling
- Update governance
- Audit-ready documentation
The product team should know what happens when model performance drops, when usage changes, when new patient populations appear, or when an integration begins sending unexpected data.
AI SaMD teams should also plan how to communicate changes to users. Transparency matters because clinicians need to understand what the software does, what it does not do, and how outputs should be interpreted.
Where CitrusBits Fits
CitrusBits helps MedTech and HealthTech teams design, develop, integrate, and modernize healthcare software products, including AI-enabled workflows, SaMD platforms, EHR-connected systems, medical device software, and healthcare automation products.
Our work can support:
- AI SaMD product planning
- Healthcare software architecture
- AI workflow development
- EHR and interoperability integration
- Data pipelines and dashboards
- Human-centered product design
- Secure cloud infrastructure
- DevOps and DevSecOps
- Post-launch optimization
- Product modernization
For regulated AI software, we work best as the technical execution partner alongside your clinical, regulatory, quality, and product stakeholders.
Final Thoughts
Developing AI Software as a Medical Device is not only an AI challenge. It is a product, regulatory, clinical, data, architecture, and lifecycle challenge.
The teams that succeed are the ones that define the intended use early, design around risk, validate with the right evidence, plan for FDA considerations, and treat post-market monitoring as part of the product itself.
AI-powered medical devices can create meaningful clinical value, but only when the software is designed to be safe, explainable, secure, monitored, and ready for real healthcare workflows.
Talk to an AI SaMD Development Expert
Frequently Asked Questions (FAQs)
Q: What is AI Software as a Medical Device?
Ans: AI Software as a Medical Device is software that uses AI or machine learning for a medical purpose, such as diagnosis, monitoring, prediction, triage, or treatment support, without being part of a hardware medical device.
Q: How do I build AI-powered SaMD?
Ans: Start with intended use, classification, workflow mapping, data strategy, model validation, architecture, risk management, cybersecurity, human review, and post-market monitoring.
Q: What regulations apply to AI SaMD?
Ans: In the U.S., AI SaMD may be subject to FDA medical device requirements, software documentation expectations, quality system requirements, cybersecurity expectations, PCCP guidance, CDS guidance where applicable, and privacy obligations such as HIPAA when PHI is involved.
Q: What is AI SaMD FDA classification?
Ans: AI SaMD FDA classification depends on intended use, risk, clinical claims, user, output, and potential harm if the software is wrong. Some products may follow 510(k), De Novo, or PMA pathways depending on the device type and risk profile.
Q: What is PCCP for AI medical devices?
Ans: A Predetermined Change Control Plan is a plan reviewed by FDA as part of a marketing submission for an AI-enabled device. It describes certain future modifications and how they will be validated and controlled after authorization.
Q: What architecture should AI medical device software use?
Ans: AI medical device software should use an architecture that separates data pipelines, model services, application logic, integrations, governance, monitoring, security, audit logging, and update controls.
